ClinicalTrials.gg
CompletedNCT06870162Updated Nov 5, 2026

Pain Disengagement Training (Open Pilot)

An interventional study of Pain Disengagement Training in Chronic Musculoskeletal Pain, sponsored by Massachusetts General Hospital. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Nov 5, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 155 studies in Musculoskeletal Pain with a site in United States — 29 open to participants now, 35 under way, 1 of them phase 3. Musculoskeletal Pain · United States.

Enrollment
125th of 136
13 · median 60
Started
2025
with 10 others
No phase
114 of 155
22 open now
Registered
131st of 155
by date
Lead sponsor
5 of 155
Massachusetts General Hospital

Among the 155 studies in Musculoskeletal Pain with a site in United States, this one is the 125th largest by enrollment of the 136 interventional ones that give a count, is one of 11 that started in 2025, is one of 114 with no phase, and was the 131st registered.

Musculoskeletal Pain

518 studies on the registry are indexed under Musculoskeletal Pain; 127 are open to participants now.

Browse Musculoskeletal Pain studies →

Open to participants now

29 of the 155 studies in Musculoskeletal Pain with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 66 Musculoskeletal Pain studies recruiting now, 30 (45%) set no upper age limit and 30 (45%) stop at 75 or younger; 8 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 155 studies in Musculoskeletal Pain with a site in United States, or all of them as a file.
02

Study summary

The investigators aim to conduct an open pilot trial to determine the initial feasibility of a self-directed writing-based intervention in individuals with chronic musculoskeletal pain and elevated pain catastrophizing. The investigators will assess the feasibility of recruitment, acceptability of the treatment, credibility and participant satisfaction, treatment adherence, and feasibility of assessments following pre-specified benchmarks.

Read the detailed description

Mind-body interventions are some of the most effective treatments for chronic pain, yet due to lack of resources, many are inaccessible to the patients who need them. The investigators seek to fill this gap by developing and testing Pain Disengagement Training (PDT) for the treatment of chronic pain catastrophizing, a key risk factor for pain interference. The investigators will administer the PDT treatment in a small number (approximately 10) of participants to evaluate initial benchmarks (the feasibility of recruitment, acceptability of the treatment, credibility and participant satisfaction, treatment adherence, and feasibility of assessments) and to assess participants' experience with the intervention using qualitative exit interviews. Results will inform the refinement of the intervention for a future larger trial.

03

Conditions studied

  • Chronic Musculoskeletal Pain

Browse trials for

Keywords

  • pain catastrophizing
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Outpatient adults (i.e., greater than or equal to 18)
  2. Has self reported chronic musculoskeletal pain (i.e., pain persisting for at least 3 months)
  3. Pain score greater than or equal to 4 (moderate) on the Numerical Rating Scale
  4. Pain catastrophizing score greater than or equal to 20 on Pain Catastrophizing Scale
  5. Willingness to engage in a writing-based intervention and self-reported ability to write or type for at least 30 minutes in a sitting
  6. Received care at Massachusetts General Hospital
  7. English verbal and writing fluency

Exclusion criteria

Exclusion Criteria:

  1. change in therapy or medication in the past 3 months
  2. Severe untreated mental health condition (e.g., psychosis)
  3. Active suicidality with history of plan or current intent
  4. Serious illness expected to worsen in the next 6 months (e.g., cancer)
  5. Untreated substance use problem that, per patient's self-report, would interfere with the ability to complete the intervention.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Pain Disengagement Training

    The intervention involves approximately 8 sessions. The first session will involve a psychoeducation component describing the association between negative emotions and pain and the rationale for the intervention strategies. The intervention sessions will consist of approximately 30 minutes of writing alternating between imaginal exposure writing and positive writing periods alternating back and forth (e.g., 3-5 minutes of imaginal exposure writing followed by 3-5 minutes of positive writing before returning to imaginal exposure writing, etc.). Exposure writing will involve writing about a pain-related catastrophic worry repeatedly until it becomes less anxiety-provoking. The positive writing topics will change with each prompt and will be structured by session theme (e.g., values/goals, meaningful activities). They will also complete between session practice by setting aside a time for worrying and then completing a meaningful activity.

    Behavioral: Pain Disengagement Training

Interventions

  • BehavioralPain Disengagement Training

    The intervention involves approximately 8 sessions. The first session will involve a psychoeducation component describing the association between negative emotions and pain and the rationale for the intervention strategies. The intervention sessions will consist of approximately 30 minutes of writing alternating between imaginal exposure writing and positive writing periods alternating back and forth (e.g., 3-5 minutes of imaginal exposure writing followed by 3-5 minutes of positive writing before returning to imaginal exposure writing, etc.). Exposure writing will involve writing about a pain-related catastrophic worry repeatedly until it becomes less anxiety-provoking. The positive writing topics will change with each prompt and will be structured by session theme (e.g., values/goals, meaningful activities). They will also complete between session practice by setting aside a time for worrying and then completing a meaningful activity.

06

What researchers measure

Primary outcomes

  1. Feasibility of recruitment

    \>70% participants approached agree to participate in the intervention

    Time frame: Baseline, post-test (6 weeks)

  2. Acceptability of treatment

    \>70% of participants attend at least 6 out of 8 sessions

    Time frame: Baseline, post-test (6 weeks)

  3. Credibility and Expectancy Questionnaire

    Measures perception that the treatment is credible and will offer improvements. Credibility (4 items) is rated from 1-9 with higher scores indicating more credibility. Expectancy is rated from 0-10 with higher scores indicating greater expectancy of improvement.

    Time frame: Baseline

  4. Client Satisfaction Questionnaire

    Measure of client satisfaction with a program or intervention. 8-item scale measured from 1 to 4 with greater scores indicating greater satisfaction.

    Time frame: Post-test (6 weeks)

  5. Adherence to intervention

    Percent of writing sections demonstrate correct themes (e.g., anxiety words in imaginal exposure writing)

    Time frame: Mid-intervention

  6. Feasibility of assessments

    \>70% of participants have no measures fully missing

    Time frame: Baseline, post-test (6 weeks)

Secondary outcomes

  1. Numerical Rating Scale

    Rating of pain intensity on a 0-10 1-item scale with greater scores indicating greater pain intensity

    Time frame: Baseline, post-test (6 weeks)

  2. Graded Chronic Pain Scale

    Measure of pain severity. 3-item scale rated from 0 to 10 with greater scores indicating greater pain severity and interference

    Time frame: Baseline, post-test (6 weeks)

  3. PROMIS Pain Interference scale

    Assesses pain interference in the past 7 days in activities, work, chores, etc. 8-item scale (1 - not at all to 5 - very much) with greater scores indicating greater pain interference.

    Time frame: Baseline, post-test (6 weeks)

  4. Brief Pain Inventory

    Assesses pain intensity (4 items) on a 0 to 10 scale with greater scores indicating worse pain intensity and interference.

    Time frame: Baseline, post-test (6 weeks)

  5. Patient Health Questionnaire - 9

    Measure of depressive symptoms. 9-item scale rated from 0 to 3 with greater scores indicating greater depressive symptoms.

    Time frame: Baseline, post-test (6 weeks)

  6. PROMIS depression scale-8

    Measure of depressive symptoms. 8-item scale rated from 1 to 5 with greater scores indicating greater depressive symptoms.

    Time frame: Baseline, post-test (6 weeks)

  7. Penn State Worry Questionnaire - abbreviated

    8-item measure of worry rated from 1 to 5 with greater scores indicating greater worry.

    Time frame: Baseline, post-test (6 weeks)

  8. Pain Catastrophizing Scale

    Assesses magnification, helplessness, and rumination in response to pain. 13-item scale rated 0 to 4 with greater scores indicating greater pain catastrophizing.

    Time frame: Baseline, post-test (6 weeks)

  9. Pain Anxiety Symptom Scale - Short Form (PASS-20)

    Assesses fear and anxiety in response to pain. 20-item scale rated 0 to 5 with greater scores indicating greater pain anxiety.

    Time frame: Baseline, post-test (6 weeks)

  10. Worry Disengagement Questionnaire

    Measures ability to shift attention from worry. 4-item scale rated from 0 to 10 with greater scores indicating greater ability to shift attention away from worry.

    Time frame: Baseline, post-test (6 weeks)

  11. Behavioral Activation for Depression Scale - Short Form

    Assesses engagement in meaningful activities. 9-item measure rated from 0 to 6 with greater scores indicating greater activity engagement.

    Time frame: Baseline, post-test (6 weeks)

  12. Positive emotion rating scale

    Assesses level of emotional intensity on a 4-item scale from 1 to 5 with greater scores indicating more positive emotionality.

    Time frame: Mid-intervention

  13. Contrast Avoidance Questionnaire-General Emotion and Worry subscales

    Measures ability to sustain negative emotionality to protect against sudden shifts in emotion. 25-item scale rated from 1 to 5 with greater scores indicating greater avoidance of contrasting emotional states.

    Time frame: Baseline, post-test (6 weeks)

  14. PROMIS meaning and purpose scale short form 4a

    4 item scale assessing meaning and fulfillment in life (1 to 5 rating scale)

    Time frame: Baseline, post-test (6-weeks)

  15. Self-Compassion Scale

    12 item 1 to 5 scale measuring self-compassion

    Time frame: Baseline, Post-test (6 weeks)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — De-identified data will include feasibility assessments, intervention measures (i.e., peak emotion during writing periods) and pre and post intervention self-report questionnaires in the open pilot.

Supporting information: Statistical analysis plan, Analytic code

Time frame: Data from this study will be deposited into the repositories no later than the end of the funded project period. Data will be available indefinitely and will only be removed from the repository if requested by NIH or other relevant institution policy.

Access criteria: Data will be stored in the Vivli repository, an NIH-approved independent, generalist global data-sharing and analytics platform. Researchers will be able to access the data by request. Investigators will need to provide evidence of their institution's IRB approval for planned analyses of the data and upon the contingency that data only be used for research and secured by electronic safeguards. Further, this agreement will state that data will be destroyed once data analysis is complete.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2025 to primary completion in Oct 2026, 11 months.

Of 226 non-industry interventional studies with no phase under Musculoskeletal Pain, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 34. This study's 11 months is below that.

Counting every sponsor, half of 239 studies reached it within 12 months; a quarter within 5 and three quarters within 32.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Dec 2026 → Oct 2026 and completion Dec 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2025
First posted
Mar 11, 2025
StartActual
Oct 14, 2025
Primary completionActual
Oct 6, 2026was Dec 2026
CompletionActual
Oct 6, 2026was Dec 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 5, 2026
Primary completion
Dec 10, 2026→Oct 6, 2026 (actual)
Nov 5, 2026
Study completion
Dec 10, 2026→Oct 6, 2026 (actual)
Nov 5, 2026
Enrollment
10 (estimated)→13 (actual)
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Recruiting→Completed
    Primary completion Dec 10, 2026→Oct 6, 2026 (now actual)
    Study completion Dec 10, 2026→Oct 6, 2026 (now actual)
    Enrollment 10 (estimated)→13 (actual)
    + 2 other changes: contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06870162
Responsible party
Katherine A McDermott (Staff psychologist, Massachusetts General Hospital) — Principal investigator
First posted
Mar 11, 2025
Start date
Oct 14, 2025
Primary completion
Oct 6, 2026
Completion
Oct 6, 2026
Last update
Nov 5, 2026

Study contacts

Katherine McDermott, PhD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion